Pulmonary embolism confounded with COVID-19 suspicion in a catatonic patient presenting to anesthesia for ECT: a case report

Naik, B Naveen; Singh, Nidhi; Aditya, Ashish; Gupta, Aakriti; Prabhakar, Nidhi; Grover, Sandeep

doi:10.1016/j.bjane.2021.02.031

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Catatonia has been described in the context of respiratory illnesses, including influenza ( Coulonjou et al, 1958 ; Wender, 1979 ) and SARS-CoV-2 ( Amouri et al, 2020 ; Brandão et al., 2021 ; Caan et al, 2020 ; Cooper and Ross, 2020 ; Ghaziuddin et al, 2021 ; Gouse et al, 2020 ; Kaur et al, 2021 ; Kopishinskaia et al., 2021 ; Kwon et al, 2021 ; Mulder et al, 2021 ; Naik et al, 2021 ; Nikayin et al, 2022 ; Raidurg et al, 2021 ; Scheiner et al, 2021 ; Torrico et al, 2021 ; Vazquez-Guevara et al., 2021 ; Zain et al, 2021 ; Zandifar and Badrfam, 2020 ), as well as in critical illnesses (e.g. sepsis, shock).…”

Section: Considerations In Special Groups and Situationsmentioning

confidence: 99%

Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology

et al. 2023

Self Cite

View full text Add to dashboard Cite

The British Association for Psychopharmacology developed an evidence-based consensus guideline on the management of catatonia. A group of international experts from a wide range of disciplines was assembled. Evidence was gathered from existing systematic reviews and the primary literature. Recommendations were made on the basis of this evidence and were graded in terms of their strength. The guideline initially covers the diagnosis, aetiology, clinical features and descriptive epidemiology of catatonia. Clinical assessments, including history, physical examination and investigations are then considered. Treatment with benzodiazepines, electroconvulsive therapy and other pharmacological and neuromodulatory therapies is covered. Special regard is given to periodic catatonia, malignant catatonia, neuroleptic malignant syndrome and antipsychotic-induced catatonia. There is attention to the needs of particular groups, namely children and adolescents, older adults, women in the perinatal period, people with autism spectrum disorder and those with certain medical conditions. Clinical trials were uncommon, and the recommendations in this guideline are mainly informed by small observational studies, case series and case reports, which highlights the need for randomised controlled trials and prospective cohort studies in this area.

show abstract